Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 91.45
-0.05 (-0.05%)
Apr 20, 2026, 3:23 PM HKT
Innovent Biologics Employees
Innovent Biologics had 7,502 employees as of December 31, 2025. The number of employees increased by 1,843 or 32.57% compared to the previous year.
Employees
7,502
Change
1,843
Growth
32.57%
Revenue / Employee
1.93M HKD
Profits / Employee
120.68K HKD
Market Cap
158.08B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,502 | 1,843 | 32.57% |
| Jun 30, 2025 | 6,190 | - | - |
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | 5,568 | 2,289 | 69.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 21,435 |
| WuXi Biologics | 13,252 |
| BeOne Medicines AG | 12,000 |
| 3SBio | 6,109 |
| Shanghai Henlius Biotech | 3,762 |
| Akeso | 3,761 |
| RemeGen | 3,048 |
| Shanghai Junshi Biosciences | 2,903 |
Innovent Biologics News
- 10 days ago - China healthcare stocks outgain Hong Kong market as Middle East roils global investments - South China Morning Post
- 10 days ago - Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases - PRNewsWire
- 20 days ago - Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema - PRNewsWire
- 25 days ago - Innovent Announces 2025 Annual Results and Business Updates - PRNewsWire
- 27 days ago - Innovent Biologics Phase 3 STAR Study Shows Efdamrofusp Alfa Effective In NAMD - Nasdaq
- 4 weeks ago - Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study - PRNewsWire
- 2 months ago - Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer - PRNewsWire
- 2 months ago - Innovent Biologics Strikes Partnership Deal With Eli Lilly - WSJ